KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+137.2%
5Y CAGR+13.8%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+137.2%/yr
vs -49.4%/yr prior
5Y CAGR
+13.8%/yr
Recent acceleration
Acceleration
+186.6pp
Accelerating
Percentile
P85
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 21.96% |
| Q3 2025 | -7.23% |
| Q2 2025 | -28.16% |
| Q1 2025 | 6.27% |
| Q4 2024 | -3.61% |
| Q3 2024 | 8.75% |
| Q2 2024 | -46.16% |
| Q1 2024 | -11.45% |
| Q4 2023 | -2.24% |
| Q3 2023 | 8.30% |
| Q2 2023 | -17.75% |
| Q1 2023 | -4.10% |
| Q4 2022 | 1.65% |
| Q3 2022 | 1.85% |
| Q2 2022 | -0.48% |
| Q1 2022 | -13.05% |
| Q4 2021 | -20.94% |
| Q3 2021 | -8.17% |
| Q2 2021 | -42.55% |
| Q1 2021 | 0.97% |
| Q4 2020 | 11.51% |
| Q3 2020 | -61.25% |
| Q2 2020 | 29.61% |
| Q1 2020 | -36.98% |
| Q4 2019 | 2.88% |
| Q3 2019 | 15.06% |
| Q2 2019 | -69.07% |
| Q1 2019 | -36.11% |
| Q4 2018 | 30.19% |
| Q3 2018 | -136.07% |
| Q2 2018 | 31.68% |
| Q1 2018 | 26.80% |
| Q4 2017 | -8.88% |
| Q3 2017 | -7.22% |
| Q2 2017 | 37.34% |
| Q1 2017 | -237.51% |
| Q3 2016 | 0.00% |
| Q2 2016 | 63.16% |
| Q1 2016 | -17.22% |
| Q4 2015 | -13.68% |